| Bioactivity | H1PVAT is a potent and selective inhibitor of poliovirus serotypes (PV-1, PV-2, PV-3), and inhibits early stage of the replication. H1PVAT interacts with viral capsid directly and protects PV against heat inactivation[1][2]. | ||||||||||||
| Target | EC50: 10 nM (PV-1), 26 nM (PV-2), 218 nM (PV-3) | ||||||||||||
| Invitro | H1PVAT (10-218 nM; 24-48 h) inhibits poliovirus strain Sabin replication in a dose-dependent manner, with EC50s of 10 nM (PV-1), 26 nM (PV-2) and 218 nM (PV-3), respectively[1].H1PVAT (30 min prior to or 1 h after PV-1 infection; 7 h) inhibits an early stage of viral replication , and only H1PVAT is administered prior to infection results reduction (>99.9%) in intracellular viral RNA levels[1].H1PVAT (50 μM; 2 min) protects PV against heat inactivation with the 50% thermal inactivation temperature increased to 52.6 ℃ and 50.8 ℃, which suggests a direct interaction between the viral capsid and H1PVAT[1]. | ||||||||||||
| Name | H1PVAT | ||||||||||||
| CAS | 351438-49-8 | ||||||||||||
| Formula | C19H14F3N5OS | ||||||||||||
| Molar Mass | 417.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Tijsma A, et al. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1. Antiviral Res. 2014 Oct;110:1-9. [2]. Tijsma A. Antiviral strategies against polio and other enteroviruses. 2018. |